$48.2
+0.06
(+0.12%)▲
0.04%
Downside
Day's Volatility :4.21%
Upside
4.17%
64.81%
Downside
52 Weeks Volatility :76.77%
Upside
33.97%
Period | Establishment Labs Holdings Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -0.68% | 6.5% | 0.0% |
6 Months | 34.09% | 7.1% | 0.0% |
1 Year | -29.78% | 9.8% | 0.0% |
3 Years | -36.56% | 14.2% | -20.2% |
Market Capitalization | 1.3B |
Book Value | $2.07 |
Earnings Per Share (EPS) | -3.17 |
Wall Street Target Price | 65.0 |
Profit Margin | -53.12% |
Operating Margin TTM | -23.77% |
Return On Assets TTM | -16.07% |
Return On Equity TTM | -404.56% |
Revenue TTM | 155.8M |
Revenue Per Share TTM | 5.91 |
Quarterly Revenue Growth YOY | -20.1% |
Gross Profit TTM | 106.6M |
EBITDA | -61.2M |
Diluted Eps TTM | -3.17 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.81 |
EPS Estimate Next Year | -0.79 |
EPS Estimate Current Quarter | -0.67 |
EPS Estimate Next Quarter | -0.42 |
What analysts predicted
Upside of 34.85%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 61.2M | ↑ 76.49% |
Net Income | -21.1M | ↓ 39.54% |
Net Profit Margin | -34.47% | ↑ 66.15% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 89.6M | ↑ 46.33% |
Net Income | -38.2M | ↑ 80.82% |
Net Profit Margin | -42.59% | ↓ 8.12% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 84.7M | ↓ 5.46% |
Net Income | -38.1M | ↓ 0.08% |
Net Profit Margin | -45.02% | ↓ 2.43% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 126.7M | ↑ 49.61% |
Net Income | -41.1M | ↑ 7.92% |
Net Profit Margin | -32.47% | ↑ 12.55% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 161.7M | ↑ 27.64% |
Net Income | -75.2M | ↑ 82.82% |
Net Profit Margin | -46.51% | ↓ 14.04% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 165.2M | ↑ 2.13% |
Net Income | -78.5M | ↑ 4.38% |
Net Profit Margin | -47.53% | ↓ 1.02% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 43.8M | ↑ 14.56% |
Net Income | -13.6M | ↓ 27.12% |
Net Profit Margin | -30.95% | ↑ 17.7% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 46.5M | ↑ 6.19% |
Net Income | -11.9M | ↓ 11.95% |
Net Profit Margin | -25.67% | ↑ 5.28% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 48.6M | ↑ 4.38% |
Net Income | -16.7M | ↑ 40.22% |
Net Profit Margin | -34.48% | ↓ 8.81% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 38.5M | ↓ 20.71% |
Net Income | -29.3M | ↑ 74.82% |
Net Profit Margin | -76.02% | ↓ 41.54% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 31.6M | ↓ 18.04% |
Net Income | -20.5M | ↓ 29.83% |
Net Profit Margin | -65.09% | ↑ 10.93% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 37.2M | ↑ 17.77% |
Net Income | -16.2M | ↓ 21.13% |
Net Profit Margin | -43.59% | ↑ 21.5% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 116.6M | ↑ 104.17% |
Total Liabilities | 47.1M | ↓ 24.18% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 116.5M | ↓ 0.04% |
Total Liabilities | 76.9M | ↑ 63.35% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 156.4M | ↑ 34.2% |
Total Liabilities | 81.4M | ↑ 5.86% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 139.5M | ↓ 10.78% |
Total Liabilities | 88.8M | ↑ 9.04% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 211.1M | ↑ 51.27% |
Total Liabilities | 219.2M | ↑ 146.93% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 268.6M | ↑ 27.28% |
Total Liabilities | 250.2M | ↑ 14.14% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 211.1M | ↑ 12.47% |
Total Liabilities | 219.2M | ↑ 17.79% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 209.4M | ↓ 0.81% |
Total Liabilities | 225.4M | ↑ 2.79% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 285.3M | ↑ 36.27% |
Total Liabilities | 230.4M | ↑ 2.25% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 270.5M | ↓ 5.18% |
Total Liabilities | 240.0M | ↑ 4.17% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 268.6M | ↓ 0.7% |
Total Liabilities | 250.2M | ↑ 4.25% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 301.8M | ↑ 12.36% |
Total Liabilities | 244.9M | ↓ 2.13% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -33.9M | ↑ 5.99% |
Investing Cash Flow | -5.7M | ↑ 578.22% |
Financing Cash Flow | 81.5M | ↑ 89.63% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -30.0M | ↓ 11.52% |
Investing Cash Flow | -7.8M | ↑ 35.51% |
Financing Cash Flow | 22.8M | ↓ 72.05% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.5M | ↓ 58.28% |
Investing Cash Flow | -5.6M | ↓ 28.42% |
Financing Cash Flow | 64.7M | ↑ 183.78% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -27.5M | ↑ 120.08% |
Investing Cash Flow | -7.2M | ↑ 28.85% |
Financing Cash Flow | 4.1M | ↓ 93.73% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -52.2M | ↑ 89.47% |
Investing Cash Flow | -34.8M | ↑ 385.7% |
Financing Cash Flow | 100.3M | ↑ 2374.21% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -14.0M | ↓ 36.23% |
Investing Cash Flow | -10.4M | ↑ 116.8% |
Financing Cash Flow | 25.0M | ↑ 1874.47% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -20.6M | ↑ 47.07% |
Investing Cash Flow | -4.3M | ↓ 58.98% |
Financing Cash Flow | 1.2M | ↓ 95.26% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -28.2M | ↑ 36.99% |
Investing Cash Flow | -9.0M | ↑ 111.52% |
Financing Cash Flow | 84.5M | ↑ 7042.18% |
Sell
Neutral
Buy
Establishment Labs Holdings Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Establishment Labs Holdings Inc | 10.44% | 34.09% | -29.78% | -36.56% | 95.45% |
![]() Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
![]() Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
![]() Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
![]() Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
![]() Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Establishment Labs Holdings Inc | NA | NA | NA | -1.81 | -4.05 | -0.16 | NA | 2.07 |
![]() Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
![]() Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
![]() Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
![]() Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Establishment Labs Holdings Inc | Buy | $1.3B | 95.45% | NA | -53.12% |
![]() Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
![]() Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
![]() Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
![]() Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
![]() Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Establishment Labs Holdings Inc
Revenue is up for the last 2 quarters, 31.56M → 37.16M (in $), with an average increase of 15.1% per quarter
Netprofit is up for the last 3 quarters, -29.27M → -16.20M (in $), with an average increase of 34.6% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 71.5%
In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 105.5%
JW Asset Management, LLC
RTW INVESTMENTS, LLC
Brown Advisory Holdings Inc
Nantahala Capital Management, LLC
JPMorgan Chase & Co
COWEN AND COMPANY, LLC
establishment labs is a global, privately held, high-tech medical device and aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants. with more than 30 years of advanced breast implant manufacturing experience, building quality breast implants has always been a natural outcome for establishment labs’ founders and top executives. as a result, motiva implants® has established a level of product innovation that always results in safety. and while we respect our past, we ́re more focused on the present and the future, one that ́s innovative, safe and progressive. we believe that these goals can be achieved by incorporating the current needs and preferences of plastic surgeons and patients into our product design.
Organization | Establishment Labs Holdings Inc |
Employees | 908 |
CEO | Mr. Juan Jose Chacon Quiros |
Industry | Health Technology |
A Spac I Acquisition Corp
$48.20
+0.12%
Keyarch Acquisition Corp
$48.20
+0.12%
Connexa Sports Technologies Inc
$48.20
+0.12%
Us Value Etf
$48.20
+0.12%
First Wave Biopharma Inc
$48.20
+0.12%
Global X Msci Next Emerging
$48.20
+0.12%
Fat Projects Acquisition Corp
$48.20
+0.12%
Capital Link Global Fintech
$48.20
+0.12%
Applied Uv Inc
$48.20
+0.12%